{"doi":"10.1093/oncolo/oyaf172","title":"Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial","abstract":"BACKGROUND: Prospective randomized data supports radiation omission in women ≥65 years who take adjuvant endocrine therapy (AET) following breast-conserving surgery. Many patients who omit radiation stop AET early due to side effects. In the POWER trial, a prospective single-arm study, patients took 90 days of preoperative endocrine therapy (pre-ET) to assess tolerance before making adjuvant treatment decisions. We hypothesized that patient-reported outcomes (PROs) during pre-ET would be heterogeneous and that 90 days was sufficient time for symptoms to develop. PATIENTS AND METHODS: PRO data from POWER trial participants was obtained before, during, and after pre-ET, including health-related quality of life (HRQoL), depression, and ET symptoms using the EORTC-QLQ, CESD-R, and BCPT-SCL tools. PRO assessments were further analyzed after stratifying patients by high or low perceived sensitivity to medicine (PSM). RESULTS: Pre-ET PROs were assessed for 75 participants. The majority (73.3%) reported symptoms during pre-ET. Only 10.7% had symptoms severe enough to stop pre-ET before 90 days. Vasomotor (42.7%) and musculoskeletal (41.3%) symptoms were the most common. HRQoL was preserved for 66.6% of participants. Patients with high PSM had more ET side effects. CONCLUSIONS: Patients developed similar side effects during pre-ET as those typically seen with AET. PROs and the impact of pre-ET on HRQoL were patient-dependent. A 90-day course of pre-ET is sufficient for patients to develop symptoms reflective of long-term AET. Future analyses will assess the association of pre-ET PROs with AET initiation and adherence.","journal":"The Oncologist","year":2025,"id":553170,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9588,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1315175,"name":"Lena M Turkheimer","orcid":"0000-0002-4460-8718","position":1,"is_corresponding":false},{"id":1345445,"name":"Jenna Schlefman","orcid":null,"position":2,"is_corresponding":false},{"id":413271,"name":"Gina R. Petroni","orcid":"0000-0002-2386-128X","position":3,"is_corresponding":false},{"id":1345446,"name":"David Brighton","orcid":null,"position":4,"is_corresponding":false},{"id":363611,"name":"Shayna L. Showalter","orcid":"0000-0001-7950-759X","position":5,"is_corresponding":false},{"id":1315176,"name":"Trish Millard","orcid":"0000-0002-6504-5387","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-19T02:54:41.819682Z","pmid":"40518662","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}